Published in Sci Rep on April 22, 2014
Visualization of aging-associated chromatin alterations with an engineered TALE system. Cell Res (2017) 0.81
Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines (2016) 0.75
MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol (2007) 168.76
High-fidelity amplification using a thermostable DNA polymerase isolated from Pyrococcus furiosus. Gene (1991) 5.65
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A (1988) 5.52
A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology (N Y) (1993) 4.49
Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 3.67
A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain. J Biol Chem (1988) 2.70
Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A (2010) 2.68
Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature (1996) 2.34
Reverse vaccinology: developing vaccines in the era of genomics. Immunity (2010) 2.25
A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods (2001) 2.15
Removal of endotoxin from recombinant protein preparations. Clin Biochem (1997) 1.95
Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol (2007) 1.93
Regulation of the immune response by antigen. Science (2001) 1.84
Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol (1985) 1.82
Synthetic peptides as antigens: pitfalls of conjugation methods. J Immunol Methods (1985) 1.76
Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions. Biotechnology (N Y) (1995) 1.61
Opportunities and challenges of developing thermostable vaccines. Expert Rev Vaccines (2009) 1.52
Peptides as antigens. Importance of orientation. J Exp Med (1986) 1.39
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One (2011) 1.28
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08
Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem (2007) 1.08
Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. Gene (1994) 1.05
Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin. Vaccine (2009) 1.05
Peptide aptamers as guides for small-molecule drug discovery. Drug Discov Today (2006) 1.05
The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology (2010) 1.04
Recombinant proteins fused to thermostable partners can be purified by heat incubation. J Biotechnol (2004) 0.98
Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol (2013) 0.97
Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95
A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin. J Mol Biol (2000) 0.92
A single point mutation (Glu85Arg) increases the stability of the thioredoxin from Escherichia coli. Protein Eng (2001) 0.91
Expression of a recombinant Toxoplasma gondii ROP2 fragment as a fusion protein in bacteria circumvents insolubility and proteolytic degradation. Protein Expr Purif (1999) 0.90
Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies. Mini Rev Med Chem (2001) 0.88
Targeting cancer with peptide aptamers. Oncotarget (2011) 0.87
Peptide aptamers for small molecule drug discovery. Methods Mol Biol (2009) 0.86
Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships. Front Immunol (2013) 0.86
Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine (2012) 0.86
Peptide dendrimers. J Pept Sci (2005) 0.85
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83
Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. Int J Cancer (2012) 0.82
Using bio-panning of FLITRX peptide libraries displayed on E. coli cell surface to study protein-protein interactions. Methods Mol Biol (2003) 0.82
Development of human papillomavirus chimaeric L1/L2 candidate vaccines. Arch Virol (2013) 0.81
Peptide aptamers: exchange of the thioredoxin-A scaffold by alternative platform proteins and its influence on target protein binding. Cell Mol Life Sci (2002) 0.81
Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model. Arch Virol (2013) 0.80
Construction and structural modeling of a single-chain Fv-asparaginase fusion protein resistant to proteolysis. Biotechnol Bioeng (2000) 0.78
Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine. Cancer Prev Res (Phila) (2015) 0.79
Secretory production of designed multipeptides displayed on a thermostable bacterial thioredoxin scaffold in Pichia pastoris. Protein Expr Purif (2016) 0.76
The SUMOylation Pathway Restricts Gene Transduction by Adeno-Associated Viruses. PLoS Pathog (2015) 0.75
Thioredoxin-Displayed Multipeptide Immunogens. Methods Mol Biol (2015) 0.75
Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine (2016) 0.75
A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses. Vaccine (2014) 0.75